News and Trends 9 Jun 2022 Ziphius Vaccines and University of Antwerp to work on RNA-based delivery methods Belgian biopharma firm Ziphius Vaccines is set to collaborate with the University of Antwerp to research and develop a lipid library for optimized delivery systems of self-amplifying RNA-based drugs (saRNA) and therapeutics. Messenger RNA (mRNA) vaccines deliver genetic instructions to cells to create proteins that then train the immune system against a pathogen, such as […] June 9, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jun 2022 Amaroq Therapeutics ‘hits early milestones’ in cancer treatment New Zealand biotech company Amaroq Therapeutics said it is progressing towards clinical trials following a promising initial development phase. The company, a start-up spun out of the University of Otago, is focused on developing a new class of therapeutics that target long non-coding RNAs (lncRNA) in cancer. Sarah Diermeier, chief scientific officer and founder of […] June 9, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2021 Patent Waiver on Covid-19 Vaccines Splits Opinions in Biotech Industry Attempts to increase global Covid-19 vaccine coverage with a temporary patent waiver have been met with hostility from many big pharma and biotech companies, but some smaller players welcome the idea. With the Covid-19 pandemic still rampaging through many countries and new viral variants popping up with alarming regularity, scuffles over who holds intellectual property […] June 15, 2021 - 5 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
In Depth 1 Mar 2021 How Are European Biotechs Tackling the Cardiovascular Disease Problem? Cardiovascular diseases may not regularly grab the headlines, but they’re the leading cause of mortality globally, making up over 30% of all deaths worldwide. While there are many established treatments on the market, there’s still a need for more effective treatments – can biotech companies provide the answer? We all know that frequent exercise, a […] March 1, 2021 - 9 minutesmins - By Farhan Mitha Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Dec 2020 A Year to Remember: The Biggest European Biotech News in 2020 The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled through. Let’s look back at some of the top moments in the last 12 months. After the many drug approvals, startup foundations, and venture capital highs we saw in 2019, it looked like 2020 was going to be a comfortable […] December 28, 2020 - 12 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 26 Mar 2020 Silence Therapeutics to Work with AstraZeneca in RNAi Deal Worth up to €3.6B AstraZeneca is recruiting RNAi specialist Silence Therapeutics to develop treatments for cardiovascular, renal, metabolic, and respiratory diseases. RNA interference, or RNAi, is a relatively new field of medicine in which therapeutic small interfering (si)RNA molecules — known as siRNA molecules — can selectively block genes and thus inhibit the production of disease-causing proteins. John Strafford, […] March 26, 2020 - 3 minutesmins - By Laura Cowen Share WhatsApp Twitter Linkedin Email
News and Trends 3 Mar 2020 Alnylam Gets Second RNAi Drug Approval from EMA US biotech Alnylam Pharmaceuticals has succeeded in getting its second RNAi drug — for treatment of rare, inherited liver diseases — approved by the European Medicines Authority just months after achieving US FDA approval for the same drug. Alnylam are well known for being pioneers in the RNA interference space. The company achieved the first […] March 3, 2020 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 3 Feb 2020 CureVac Bids to Develop First mRNA Coronavirus Vaccine RNA vaccine developer CureVac will receive a grant of up to €8.3M from a global partnership to develop an mRNA vaccine against the new coronavirus strain from China. The agreement follows on from an existing collaboration launched in 2019, when the Coalition for Epidemic Preparedness Innovations, or CEPI, granted CureVac €30M to develop facilities that […] February 3, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jan 2020 AstraZeneca Recruits RNA Biotech to Develop Metabolic Disease Therapies The UK biotech MiNA Therapeutics has launched a collaboration with AstraZeneca to develop small activating RNA drugs, which could treat metabolic diseases using targets unreachable by current medications. According to the agreement, the two partners will carry out preclinical research with the aim of generating candidate drugs based on small activating RNA, or saRNA — […] January 7, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jan 2020 BioNTech’s RNA-Boosted CAR T-Cell Therapy Shrinks Tumors in Mice A CAR T-cell therapy amplified by RNA technology, developed by BioNTech, has shown preclinical potential for tackling solid tumors, which are hard to treat with current CAR T-cell therapies. In a study published in Science, the CAR T-cell and RNA combination therapy suppressed tumors in mice implanted with human ovarian cancer for longer than regular […] January 6, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 Dec 2019 European Biotech’s Top News in 2019 With the year coming to a close, it’s time to review the most important biotech news events that took place in the European biotech industry in 2019. It has been a solid year for the European biotech industry. In 2019, venture capital funding in Europe continued to be high after a very good year in […] December 30, 2019 - 10 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 25 Nov 2019 Novartis Enters RNA Therapeutics with Medicines Company Merger Novartis is to acquire The Medicines Company and its late-stage RNA interference drug designed to protect against cardiovascular disease in twice-yearly shots. Novartis will pay €8.8B ($9.7B) to acquire The Medicines Company, which is based in the US and focuses on developing the RNA drug inclisiran for the treatment of cardiovascular disease and renal impairment. […] November 25, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email